Jundishapur Journal of Microbiology

Published by: Kowsar

Nosocomial Yeast Infections Among Cancer Patients in Egypt: Species Distribution and Antifungal Susceptibility Profile

Noha Badr El-Din El-Mashad 1 , Amina Mostafa Abdel Aal 1 , Ahmad Mohamed Elewa 1 and Mohammed Youssef Saad Elshaer 1 , *
Authors Information
1 Clinical Pathology Department, Mansoura University, Mansoura, Egypt
Article information
  • Jundishapur Journal of Microbiology: 12 (2); e82421
  • Published Online: February 6, 2019
  • Article Type: Research Article
  • Received: July 20, 2018
  • Revised: January 8, 2019
  • Accepted: January 16, 2019
  • DOI: 10.5812/jjm.82421

To Cite: El-Mashad N B E, Abdel Aal A M, Elewa A M, Saad Elshaer M Y. Nosocomial Yeast Infections Among Cancer Patients in Egypt: Species Distribution and Antifungal Susceptibility Profile, Jundishapur J Microbiol. Online ahead of Print ; 12(2):e82421. doi: 10.5812/jjm.82421.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Krishnan NS. Emerging fungal infections in cancer patients-a brief overview. Med Mycol Open Access. 2016;2:16. doi: 10.21767/2471-8521.100016.
  • 2. Alastruey-Izquierdo A, Melhem MS, Bonfietti LX, Rodriguez-Tudela JL. Susceptibility test for fungi: Clinical and laboratorial correlations in medical mycology. Rev Inst Med Trop Sao Paulo. 2015;57 Suppl 19:57-64. doi: 10.1590/S0036-46652015000700011. [PubMed: 26465371]. [PubMed Central: PMC4711191].
  • 3. McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin North Am. 2016;30(1):103-24. doi: 10.1016/j.idc.2015.10.013. [PubMed: 26739610].
  • 4. Aydemir Ö, Demiray T, Köroglu M, Aydemir Y, Altindi M. Emerge of non-albicans Candida species; evaluation of Candida species and antifungal susceptibilities according to years. Biomedical Research. 2017;28(6).
  • 5. Liao Y, Lu X, Yang S, Luo Y, Chen Q, Yang R. Epidemiology and outcome of trichosporon fungemia: A review of 185 reported cases from 1975 to 2014. Open Forum Infect Dis. 2015;2(4):ofv141. doi: 10.1093/ofid/ofv141. [PubMed: 26566536]. [PubMed Central: PMC4630454].
  • 6. Miglietta F, Letizia Faneschi M, Braione A, Palumbo C, Rizzo A, Lobreglio G, et al. Central venous catheter-related fungemia caused by Rhodotorula glutinis. Med Mycol J. 2015;56(3):E17-9. doi: 10.3314/mmj.56.E17. [PubMed: 26329371].
  • 7. Alangaden GJ. Nosocomial fungal infections: Epidemiology, infection control, and prevention. Infect Dis Clin North Am. 2011;25(1):201-25. doi: 10.1016/j.idc.2010.11.003. [PubMed: 21316001].
  • 8. Singh GK, Capoor MR, Nair D, Bhowmik KT. Spectrum of fungal infection in head and neck cancer patients on chemoradiotherapy. J Egypt Natl Canc Inst. 2017;29(1):33-7. doi: 10.1016/j.jnci.2017.01.006. [PubMed: 28258917].
  • 9. Patolia S, Kennedy E, Zahir M, Patolia S, Gulati N, Narendra D, et al. Risk factors for candida blood stream infection in medical ICU and role of colonization-A retrospective study. Br J Med Pract. 2013;6(2):a618.
  • 10. Fisher BT, Robinson PD, Lehrnbecher T, Steinbach WJ, Zaoutis TE, Phillips B, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: A systematic review. J Pediatric Infect Dis Soc. 2018;7(3):191-8. doi: 10.1093/jpids/pix030. [PubMed: 28549148].
  • 11. Sandhu R, Dahiya S, Sayal P, Budhani D. Increased role of nonalbicans Candida, potential risk factors, and attributable mortality in hospitalized patients. J Health Res Rev. 2017;4(2):78-83. doi: 10.4103/2394-2010.208115.
  • 12. Sardi JC, Scorzoni L, Bernardi T, Fusco-Almeida AM, Mendes Giannini MJ. Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol. 2013;62(Pt 1):10-24. doi: 10.1099/jmm.0.045054-0. [PubMed: 23180477].
  • 13. Zhang L, Zhou S, Pan A, Li J, Liu B. Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013. Int J Infect Dis. 2015;33:1-4. doi: 10.1016/j.ijid.2014.12.033. [PubMed: 25541294].
  • 14. Pahwa N, Kumar R, Nirkhiwale S, Bandi A. Species distribution and drug susceptibility of candida in clinical isolates from a tertiary care centre at Indore. Indian J Med Microbiol. 2014;32(1):44-8. doi: 10.4103/0255-0857.124300. [PubMed: 24399387].
  • 15. Kumari KS, Raghunath P, Harshavardhan B, Chaudhury A. Distribution of Candida albicans and the non-albicans Candida species in different clinical specimens from South India. Int J Microbiol Res. 2014;5:1-5. doi: 10.5829/idosi.ijmr.2014.5.1.8232.
  • 16. Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project). Infection. 2013;41(3):645-53. doi: 10.1007/s15010-013-0432-0. [PubMed: 23463186]. [PubMed Central: PMC3671106].
  • 17. Ding X, Yan D, Sun W, Zeng Z, Su R, Su J. Epidemiology and risk factors for nosocomial non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China. Med Mycol. 2015;53(7):684-90. doi: 10.1093/mmy/myv060. [PubMed: 26229153].
  • 18. Sharma Y, Chumber SK, Kaur M. Studying the prevalence, species distribution, and detection of in vitro production of phospholipase from candida isolated from cases of invasive candidiasis. J Glob Infect Dis. 2017;9(1):8-11. doi: 10.4103/0974-777X.199995. [PubMed: 28250619]. [PubMed Central: PMC5330047].
  • 19. Magalhaes YC, Bomfim MR, Melonio LC, Ribeiro PC, Cosme LM, Rhoden CR, et al. Clinical significance of the isolation of Candida species from hospitalized patients. Braz J Microbiol. 2015;46(1):117-23. doi: 10.1590/S1517-838246120120296. [PubMed: 26221096]. [PubMed Central: PMC4512074].
  • 20. Siqueira RA, Doi AM, de Petrus Crossara PP, Koga PCM, Marques AG, Nunes FG, et al. Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2((R)) and Sensititre YeastOne((R)). Rev Iberoam Micol. 2018;35(2):83-7. doi: 10.1016/j.riam.2017.11.001. [PubMed: 29580699].
  • 21. Marcos-Zambrano LJ, Puig-Asensio M, Perez-Garcia F, Escribano P, Sanchez-Carrillo C, Zaragoza O, et al. Candida guilliermondii complex is characterized by high antifungal resistance but low mortality in 22 cases of candidemia. Antimicrob Agents Chemother. 2017;61(7). doi: 10.1128/AAC.00099-17. [PubMed: 28438935]. [PubMed Central: PMC5487632].
  • 22. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48(4):1366-77. doi: 10.1128/JCM.02117-09. [PubMed: 20164282]. [PubMed Central: PMC2849609].
  • 23. Czaika V, Nenoff P, Glockner A, Becker K, Fegeler W, Schmalreck AF. Detection of azole susceptibility patterns in clinical yeast strains isolated from 1998 to 2008. New Microbiol. 2014;37(4):465-94. [PubMed: 25387285].
  • 24. Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61 Suppl 6:S612-7. doi: 10.1093/cid/civ791. [PubMed: 26567278]. [PubMed Central: PMC4643482].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments